Keywords: MASH, efimosfermin, FGF-21, advanced fibrosis, cirrhosis, GLP-1, resmetirom Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver disease worldwide, with an estimated prevalence of MASLD reported to be at 38%, suggesting that 1 in 3 people has MASLD
Balancing the risks and benefits of sun exposure [35:30]
Appetite and dietary intake can be assessed through patient-reported outcomes, food diaries, or validated questionnaires
This means: Fewer middle-of-the-night wake-ups More consistent, deeper sleep Better sleep timing and rhythm Reduced Inflammation Poor sleep and inflammation create a vicious cycle
Its like cognitive and emotional bandwidth suddenly opens up